...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of psychiatric practice. >The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.
【24h】

The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.

机译：辅助使用二甲双胍治疗或预防非典型抗精神病药引起的体重增加：综述。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients with schizophrenia have a greater incidence of being overweight or obese compared with the general population. Such individuals are often treated with second-generation (atypical) antipsychotics (SGAs), which are associated with weight gain, dyslipidemia, and other metabolic derangements. As a result, frequent monitoring of weight and other metabolic parameters is recommended. In addition, several pharmacologic strategies to help prevent or reduce SGA-induced weight gain have been proposed. Despite this, clinicians often struggle to manage obesity and metabolic issues in such patients. Metformin has attracted attention as a potential treatment option because it is thought to result in weight reduction and improved glycemic control in obese patients with and without type 2 diabetes mellitus. This article focuses on relevant pharmacologic aspects of metformin and reviews currently available evidence on the use of metformin as an augmentation agent for the treatment or prevention of SGA-induced weight gain.
机译：与普通人群相比，精神分裂症患者的超重或肥胖发生率更高。此类个体通常接受第二代（非典型）抗精神病药（SGA）的治疗，这与体重增加，血脂异常和其他代谢异常有关。因此，建议经常监测体重和其他代谢参数。另外，已经提出了几种有助于预防或减少SGA引起的体重增加的药理策略。尽管如此，临床医生仍常常难以控制此类患者的肥胖和代谢问题。二甲双胍作为一种潜在的治疗方法引起了人们的注意，因为据信它可导致肥胖患者（无论是否患有2型糖尿病）减轻体重并改善血糖控制。本文重点关注二甲双胍的相关药理学方面，并综述了有关使用二甲双胍作为增强剂治疗或预防SGA引起的体重增加的现有证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号